Search Result

Results for "

aggressiveness

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (3) Cathepsin (1) CD19 (1) CDK (2) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Glutaminase (1) HDAC (3) Histone Methyltransferase (1) iGluR (1) IKK (1) Liposome (1) mAChR (1) NF-κB (1) Parasite (1) Sodium Channel (2) TAM Receptor (1)
By Research Areas:	Cancer (17) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (4)
Oligonucleotides:	Cationic Lipids (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153614

Ac-VLPE-FMK Ac-Val-Leu-Pro-Glu(OMe)-CH2F	Cathepsin	Cancer
Ac-VLPE-FMK, a tetrapeptidyl mono-fluoromethyl ketone (m-FMK), is a Cat-B and Cat-L inhibitor. Ac-VLPE-FMK can be used for the research of cancer aggressiveness .

HY-17612

Evenamide NW-3509	Sodium Channel	Neurological Disease
Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (K_i=0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness .

HY-141519

PI-55	Parasite	Infection
PI-55 is a specific cytokinin receptor inhibitor. PI-55 is structurally related to 6-benzylaminopurine (BAP) and was shown to inhibit competitively BAP binding on Arabidopsis-specific receptors CRE1/AHK4 and AHK3. PI-55 inhibits cytokinins induced haustorium formation and increased parasite aggressiveness .

HY-148559

4A3-SC8	Liposome	Cancer
4A3-SC8 is a modular degradable dendrimer that enables small RNAs to extend survival in an aggressive liver cancer model .

HY-119377

UPGL00004	Glutaminase	Cancer
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC₅₀=29 nM; K_d=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines .

HY-17612A

Evenamide hydrochloride NW-3509 hydrochloride	Sodium Channel	Neurological Disease
Evenamide hydrochloride is an orally available voltage-gated sodium channel (VGSC) blocker (K_i=0.4 μM) for the research of schizophrenia. Evenamide hydrochloride shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness .

HY-17419A

(R)-Ifosfamide	Others	Cancer
(R)-Ifosfamide is a chemotherapeutic agent primarily used in the treatment of aggressive tumors such as rhabdomyosarcoma, exhibiting alkylating activity that interferes with DNA replication.

HY-139126

(±)-Muscarine chloride DL-Muscarin chloride	mAChR	Neurological Disease
(±)-Muscarine chloride is the racemate of Muscarine chloride. Muscarine is a prototype muscarinic acetylcholine receptor agonist .

HY-114056

AS115	Others	Cancer
AS115 is a potent and selective KIAA1363 inactivator with IC₅₀ value of 150 nM. KIAA1363 is a 2-acetyl monoacylglycerol ether (MAGE) hydrolase that is upregulated in aggressive cancers of various tissues .

HY-164500

MC3629	Apoptosis Histone Methyltransferase	Cancer
MC3629 is an inhibitor of histone methyltransferase (EZH2) with anti-tumor activity. MC3629 inhibits SHH MB cancer cell proliferation and self-renewal and induces apoptosis. MC3629 can be used to study drug resistance in tumor aggressiveness .

HY-128587

Mevociclib 4 Publications Verification SY-1365	CDK	Cancer
Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a K_i of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .

HY-144782

HDAC10-IN-2	HDAC Autophagy	Cancer
HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-144779

HDAC10-IN-1	HDAC Autophagy	Cancer
HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-144782A

HDAC10-IN-2 hydrochloride	HDAC Autophagy	Cancer
HDAC10-IN-2 hydrochloride (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 hydrochloride modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-121704

SR 57227A free base	iGluR	Neurological Disease
SR 57227A Free base is a highly selective compound for both peripheral and central 5-HT3 receptors and acts as an inhibitor of NMDA receptor-mediated responses in rat cortical pyramidal cells, demonstrating antidepressant-like effects in rats while reducing isolation-induced aggressive behavior.

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-152189

S19-1035	Others	Cancer
S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC₅₀ value of 3.04 nM. S19-1035 can be used for the research of tumor .

HY-143587

CDK7-IN-2	CDK	Cancer
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1) .

HY-W004305

Hexadecanal Palmitaldehyde	Endogenous Metabolite	Metabolic Disease
Hexadecanal (Palmitaldehyde) , a volatile long-chain aliphatic aldehyde, is emitted from human feces, skin, and breath. The receptor for hexadecanal(OR37B) is highly conserved across mammals. Hexadecanal may exert its effects by modulating functional connectivity between the brain substrates of social appraisal and the brain substrates of aggressive execution. Also, Hexadecanal is confirmed to be highly deterrent to the ant Lasius niger. Hexadecanal is promising for the research of startle responses and aggression

HY-147008

XP-524	Epigenetic Reader Domain	Cancer
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-164480

GTCpFE	IKK NF-κB	Inflammation/Immunology Cancer
GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44 ⁺ CD24 ^- immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-W107409

Meridianin C	Others	Cancer
Meridianin C is a marine natural product with anticancer activity. Meridianin C has significant inhibitory effects on four different human tongue cancer cells (YD-8, YD-10B, YD-38 and HSC-3). Meridianin C most strongly reduced the growth of YD-10B cells, the most aggressive and tumorigenic of the cell lines tested. Meridianin C also induced significant accumulation of large vesicles in YD-10B cells, validating its function through macrophagocytosis. Meridianin C reduces cellular levels of Dickkopf-related protein-3 (DKK-3), a known negative regulator of macrophagy. Meridianin C affects macrophagocytosis by downregulating DKK-3, thereby affecting cell proliferation .

Cat. No.	Product Name

HY-L201

Cell Proliferation Compound Library	2,089 compounds
Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others. MCE collects 2,089 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

Cell Proliferation Compound Library

2,089 compounds

Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.

MCE collects 2,089 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

Cat. No.	Product Name	Target	Research Area